Bristol-Myers Squibb employees cycle Coast to Coast to raise money and awareness for cancer research

Bristol-Myers Squibb Today, the first of six teams of Bristol-Myers Squibb Company (NYSE:BMY) oncology employees set out from Cannon Beach on the Oregon coast on the first leg of the 2016 Coast 2 Coast 4 Cancer Ride , a 21-day cycling ride that will bring together 80 riders to cover approximately 2,800 miles on a mission for cancer patients and their loved ones by raising money for Stand Up To Cancer's innovative cancer research programs.

As part of the 2016 Coast 2 Coast 4 Cancer Ride , Bristol-Myers Squibb will match funds raised dollar-for-dollar up to $500,000, to support Stand Up To Cancer, whose collaborative "Dream Teams" of scientific researchers are working together to accelerate cancer research and to provide new treatments to patients. Last year's ride raised $841,000 for Stand Up To Cancer research and this year the goal is even higher - the Coast 2 Coast 4 Cancer Ride aims to reach $1,000,000 in donations.

"I could not be prouder of these riders, many of whom spend the majority of their time in an office and not on a bike. But they are committed to doing whatever it takes to help patients fighting cancer because we all take this cause very personally," said Chris Boerner, PhD, president and head of U.S. commercial operations, Bristol-Myers Squibb. "Everyone on these teams is riding for someone they know who has been touched by cancer. This year, I’m riding for my late cousin, whose strength in fighting stomach cancer inspired me to dedicate my professional career to fighting cancer."

One of this year's riders, Lee Krug, MD, explained, "Like so many Coast 2 Coast 4 Cancer Ride team members, I have seen the devastating impact that cancer can have on patients and their loved ones, but also the strength and endurance that they so often show. They really are our inspiration on the road. This ride is about hope and about our combined efforts for patients."

"One in two men and one in three women in the U.S. will be affected by cancer, so we all have someone we can stand up for. For the third year in a row, the Coast 2 Coast 4 Cancer Ride is standing alongside us as we work to make every person diagnosed with cancer a survivor," said Katie Couric, Yahoo Global News anchor and Stand Up To Cancer co-founder. "You take these incredibly dedicated riders, and you combine them with Bristol-Myers Squibb's commitment to match money raised, dollar-for-dollar, up to $500,000, and what you have is a truly powerful, winning team. That's what patients fighting cancer deserve, and our hope is that everyone will join us in supporting the Coast 2 Coast 4 Cancer Ride effort."

For more information about this epic team effort and to follow the riders as they cross the country, visit cancerbikeride.org.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry's resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, Ph.D., conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]